Journal of Breast Cancer,
Год журнала:
2018,
Номер
21(3), С. 233 - 233
Опубликована: Янв. 1, 2018
Breast
cancer
has
the
highest
incidence
among
all
malignancies
diagnosed
in
women.
Therapies
have
significantly
improved
over
years
due
to
extensive
molecular
and
clinical
research;
a
large
number
of
cases,
targeted
therapies
provided
better
prognosis.
However,
one
specific
subtype
remains
elusive
therapies-the
triple-negative
breast
cancer.
This
immunohistochemically
defined
is
resistant
both
endocrine
therapies,
leading
its
poor
A
field
that
great
promise
current
research
epigenetics.
By
studying
epigenetic
mechanisms
underlying
tumorigenesis-DNA
methylation,
histone
modifications,
noncoding
RNAs-advances
treatment,
diagnosis,
prevention
are
possible.
review
aims
synthesize
discoveries
been
made
related
Cancer Medicine,
Год журнала:
2019,
Номер
8(5), С. 1958 - 1975
Опубликована: Апрель 3, 2019
Traditional
Chinese
medicine
(TCM)
has
been
practiced
for
thousands
of
years
and
at
the
present
time
is
widely
accepted
as
an
alternative
treatment
cancer.
In
this
review,
we
sought
to
summarize
molecular
cellular
mechanisms
underlying
chemopreventive
therapeutic
activity
TCM,
especially
that
herbal
medicine-derived
phytochemicals
curcumin,
resveratrol,
berberine.
Numerous
genes
have
reported
be
involved
when
using
TCM
treatments
so
selectively
highlighted
role
a
number
oncogene
tumor
suppressor
in
therapy.
addition,
impact
on
DNA
methylation,
histone
modification,
regulation
noncoding
RNAs
discussed.
Furthermore,
studies
therapy
modulate
microenvironment
eliminate
cancer
stem
cells.
The
information
compiled
review
will
serve
solid
foundation
formulate
hypotheses
future
TCM-based
Nanomedicine,
Год журнала:
2017,
Номер
12(9), С. 1075 - 1089
Опубликована: Апрель 25, 2017
In
recent
decades,
colloidal
selenium
nanoparticles
have
emerged
as
exceptional
species
with
reported
chemopreventative
and
therapeutic
properties.
This
has
sparked
widespread
interest
in
their
use
a
carrier
of
agents
results
displaying
synergistic
effects
its
cargo
improved
anticancer
activity.
Functionalization
remains
critical
step
nanoparticles'
development
for
application
gene
or
drug
delivery.
this
review,
we
highlight
developments
the
synthesis
functionalization
strategies
used
cancer
delivery
systems.
We
also
provide
an
update
preclinical
studies
utilizing
therapeutics.
Diabetes Obesity and Metabolism,
Год журнала:
2018,
Номер
20(7), С. 1553 - 1562
Опубликована: Фев. 21, 2018
There
is
a
growing
body
of
evidence
that
links
epigenetic
modifications
to
type
2
diabetes.
Researchers
have
more
recently
investigated
effects
commonly
used
medications,
including
those
prescribed
for
diabetes,
on
processes.
This
work
reviews
the
influence
widely
antidiabetic
drug
metformin
epigenomics,
microRNA
levels
and
subsequent
gene
expression,
potential
clinical
implications.
Metformin
may
activity
numerous
modifying
enzymes,
mostly
by
modulating
activation
AMP-activated
protein
kinase
(AMPK).
Activated
AMPK
can
phosphorylate
substrates,
enzymes
such
as
histone
acetyltransferases
(HATs),
class
II
deacetylases
(HDACs)
DNA
methyltransferases
(DNMTs),
usually
resulting
in
their
inhibition;
however,
HAT1
be
increased.
has
also
been
reported
decrease
expression
multiple
methyltransferases,
increase
III
HDAC
SIRT1
DNMT
inhibitors.
these
alterations
epigenome
contribute
properties
and,
potentially,
protect
against
cancer,
cardiovascular
disease,
cognitive
decline
aging.
The
microRNAs
are
reportedly
influenced
treatment
confer
anticancer
activities.
However,
act
both
acetylation,
methylation,
significant
degree
uncertainty
exists
concerning
overall
effect
epigenome,
health
users.
Journal of Biomedical Science,
Год журнала:
2021,
Номер
28(1)
Опубликована: Апрель 11, 2021
Abstract
Epigenetic
drug
discovery
field
has
evidenced
significant
advancement
in
the
recent
times.
A
plethora
of
small
molecule
inhibitors
have
progressed
to
clinical
stage
investigations
and
are
being
explored
exhaustively
ascertain
conclusive
benefits
diverse
malignancies.
Literature
precedents
indicates
that
substantial
amount
efforts
were
directed
towards
use
epigenetic
tools
monotherapy
as
well
combination
regimens
at
level,
however,
preclinical/preliminary
explorations
inclined
identification
prudent
approaches
can
leverage
anticancer
potential
single
agents
only.
This
review
article
presents
an
update
FDA
approved
drugs
along
with
undergoing
different
cancer
types.
detailed
discussion
pragmatic
strategies
expected
steer
progress
therapy
through
implementation
emerging
such
PROTACS
CRISPR/Cas9
logical
ways
for
scaffold
fabrication
selectively
approach
enzyme
isoforms
pursuit
garnering
amplified
antitumor
effects
been
covered.
In
addition,
compilation
also
rational
construction
multi-targeting
assemblages
employing
previously
identified
pharmacophores
alternatives
therapy.
Cell Death Discovery,
Год журнала:
2024,
Номер
10(1)
Опубликована: Янв. 15, 2024
Abstract
Epigenetic
dysregulation
is
a
common
feature
of
myriad
human
diseases,
particularly
cancer.
Defining
the
epigenetic
defects
associated
with
malignant
tumors
has
become
focus
cancer
research
resulting
in
gradual
elucidation
cell
regulation.
In
fact,
most
stages
tumor
progression,
including
tumorigenesis,
promotion,
and
recurrence
are
accompanied
by
alterations,
some
which
can
be
reversed
drugs.
The
main
objective
therapy
era
personalized
precision
medicine
to
detect
biomarkers
improve
risk
assessment,
diagnosis,
targeted
treatment
interventions.
Rapid
technological
advancements
streamlining
characterization
molecular
changes
cancers
have
propelled
drug
development.
This
review
summarizes
mechanisms
discusses
past
present
examples
inhibitors
diagnosis
treatment,
an
emphasis
on
development
enzyme
or
final
part,
prospect
precise
considered
based
better
understanding
abnormalities
Cancer
is
a
global
public
health
concern.
Alterations
in
epigenetic
processes
are
among
the
earliest
genomic
aberrations
occurring
during
cancer
development
and
closely
related
to
progression.
Unlike
genetic
mutations,
reversible,
which
opens
possibility
for
novel
pharmacological
treatments.
Non‑coding
RNAs
(ncRNAs)
represent
an
essential
mechanism,
emerging
evidence
links
ncRNAs
carcinogenesis.
Epigenetic
drugs
(epidrugs)
group
of
promising
target
therapies
treatment
acting
as
coadjuvants
reverse
drug
resistance
cancer.
The
present
review
describes
central
malignant
transformation
explains
how
epidrugs
DNA
methylation,
histone
modifications
ncRNAs.
Furthermore,
clinical
trials
focused
on
evaluating
effect
these
alone
or
combination
with
other
anticancer
ncRNA‑based
discussed.
use
promises
be
effective
tool
reversing
some
patients
